Kaken Pharmaceutical Co Ltd
TSE:4521
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1), the stock would be worth ¥3 765.21 (9% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | ¥4 115 |
0%
|
| 3-Year Average | 1 | ¥3 765.21 |
-9%
|
| 5-Year Average | 1 | ¥3 939.37 |
-4%
|
| Industry Average | 1.6 | ¥6 115.1 |
+49%
|
| Country Average | 1.4 | ¥5 441.29 |
+32%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
K
|
Kaken Pharmaceutical Co Ltd
TSE:4521
|
155.8B JPY | 1.1 | -40.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 32.7 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 6.8 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 5.9 | 28.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 6 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 5.4 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.6 | 10.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 1.8 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 6.4 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.4 |
| 70th Percentile | 2.1 |
| Max | 31 732 017.6 |
Other Multiples
Kaken Pharmaceutical Co Ltd
Glance View
Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.